Filing Details

Accession Number:
0001562180-20-002967
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-04-08 21:42:18
Reporting Period:
2020-04-06
Accepted Time:
2020-04-08 21:42:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1689813 Biohaven Pharmaceutical Holding Co Ltd. BHVN () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1027035 W John Childs C/o Biohaven Pharmaceuticals, Inc.
215 Church Street
New Haven CT 06510
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Disposition 2020-04-06 144,659 $31.23 2,682,279 No 4 S Direct
Common Shares Disposition 2020-04-06 5,341 $31.76 2,676,938 No 4 S Direct
Common Shares Disposition 2020-04-07 81,090 $30.54 2,595,848 No 4 S Direct
Common Shares Disposition 2020-04-07 10,908 $31.55 2,584,940 No 4 S Direct
Common Shares Disposition 2020-04-07 93,268 $32.92 2,491,672 No 4 S Direct
Common Shares Disposition 2020-04-07 14,734 $33.26 2,476,938 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Shares 10,000 Indirect By John W Childs 2013 Revocable Trust
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.70 - $31.6925, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.70 - $31.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.095 - $31.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.095 - $32.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.11 - $33.105, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.11 - $33.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.